Monophasic, Cohesive-polydensified-matrixCrosslinking-technology-based Hyaluronic AcidFiller for the Treatment of Facial Lipoatrophyin HIV-infected Patients
June 2010 | Volume 9 | Issue 6 | Case Reports | 690 | Copyright © June 2010
Tatjana Pavicic MD, Thomas Ruzicka MD, Hans-Christian Korting MD, Gerd Gauglitz MD MMS
Human immunodeficiency virus (HIV)-associated facial lipoatrophy (FLA) represents a common and highly stigmatizing side effect of
retroviral therapy. By causing loss of subcutaneous adipose tissue mainly in the cheek, temple and periocular area, FLA can significantly
affect the patient’s quality of life, both physically and psychologically. A limited quantity of data has been published on various
filling substances for the management of FLA. Here, the authors present two patients with HIV-associated FLA successfully treated
with a novel HA filler over a period of 24 months.